MeiraGTx lands up to $400M to accelerate commercialization of late-stage gene therapies

MeiraGTx secured up to $400 million from Oberland Capital to push its late-stage gene therapies toward launch, anchored by an initial $125 million loan with low single-digit royalties and a $10 million equity stake. The deal also includes up to $50 million in milestones for FDA approvals (one per program for bota-vec and AAV2-hAQP1), up to $100 million more via mutual commitments, and a right for Oberland to buy an additional $15 million in equity. In addition, $50 million could follow a positive AQUAx2 phase 2 readout for dry mouth. Beyond bota-vec and AAV2-hAQP1, MeiraGTx is advancing AAV-GAD for Parkinson’s, with a 2029 follow-up study, and noted a 2025 Lilly license for AAV-AIPL1, highlighting a pipeline with several near-term regulatory milestones.